Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
Date:11/9/2010

sary.

Upcoming Corporate PresentationsArena is planning to present at upcoming investment and industry conferences, including:

  • Piper Jaffray 22nd Annual Health Care Conference, November 30-December 1, 2010, New York, New York
  • 29th Annual J.P. Morgan Healthcare Conference, January 10-13, 2011, San Francisco, California

  • About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States following FDA approval of the New Drug Application for lorcaserin.

    Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

    Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about BLOOM-DM, including providing support for lorcaserin's profile; addressing recommendations in the complete response letter for lorcaserin; the advancement, therapeutic indication and use, safety, efficacy, tolerability, mechanism of action, scheduling and regulatory review, approval, commercialization and potential of lorcaserin; the termination of the Ortho-McNeil-Janssen collaboration and related expectations and future activities; the therapeutic indication and use, safety, efficacy, tolerability, mechanism of action and potential of APD597 alone and in combination; the therapeutic indication and use, mechanism of action and exposures of APD916; the Eisai collaboration
    '/>"/>

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
    2. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
    3. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
    4. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
    5. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
    6. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
    7. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
    8. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
    9. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
    10. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
    11. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)... 2015  CytRx Corporation (CYTR), a biopharmaceutical research ... financial results for the three months ended March ... accomplishments and upcoming milestones for its clinical development ... the early months of 2015, including the announcement ... aldoxorubicin in patients with soft tissue sarcoma, and ...
    (Date:5/1/2015)... , May 1, 2015 The Institute for ... health literacy award winners. The IHA Health Literacy Awards ... an impact on the practice of educating or empowering ... IHA gives awards in three categories: innovative programs, published ... Health Literacy Hero award. In the area ...
    (Date:5/1/2015)... -- Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC ) ... 31, 2015, as well as general business updates. Due ... will be held. Key Highlights , ... increased to $206 million from $119 million for the ... ® (ibrutinib) net product revenue of $247 million ...
    Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Institute for Healthcare Advancement Announces 2015 Award Winners 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25
    ... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
    ... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
    Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
    (Date:5/3/2015)... SpineFrontier, a Less Exposure Surgery (LES) technology company, ... market their new sacroiliac joint fusion screw, the SIJ ... and is compatible with both lateral and alternate posterior ... researched and refined by SpineFrontier, the first company to ... conjunction with a sacroiliac joint fusion system like this. ...
    (Date:5/2/2015)... As one of only 30 Illinois companies to ... Achievement and Recognition Program (SHARP) certification, Essentra Specialty ... Illinois Department of Labor to host this special event. ... by the Occupational Safety and Health Administration’s (“OSHA”) Onsite ... meet or exceed all of the necessary regulations and ...
    (Date:5/2/2015)... “ ActOn ” was featured on NewsWatch ... at the latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... organizations to make a difference. , In this material world, ... that aren’t about money, which is why those things should ...
    (Date:5/2/2015)... We are pleased to announce the Sun ... one of the Top Workplaces of 2015. , The ... field for their ethics and standards of excellence. The ... their educational efforts. The Delray Recovery Center prides itself ... purpose – to help individuals heal from the disease ...
    (Date:5/2/2015)... May 02, 2015 Kare Visits LLC. launched ... for busy caregivers. Kare Visits offers relief for caregivers ... living facilities. According to the Caregiver Action Network, ... average of 20 hours a week caring for an elderly ... cost to hire a nurse, a caregiver is now empowered ...
    Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2
    ... Britain’s biggest supermarket, TESCO, was in public glare for the wrong ... of land and for not being party to a movement that ... Standards Agency got after Tesco, soon after the latter rejected the ... has made profits of over ?2 billion last year and a ...
    ... in the 'Pongala Mahotsavam,' festival at the Attukal Bhagavathy temple, ... began on March 5 and will culminate as a grand ... a very auspicious and important festival of this temple, which ... The devotees make a dish of rice and jaggery as ...
    ... decided to provide health insurance to approximately 80,000 employers ... funding for the insurance would be contributed by the ... ,Mike Huckabee of the Arkansas Government has ... employees. This move is anticipated to yield considerable revenue ...
    ... resentment against the NHS proposal to allow nurses to ... the move as being equivalent to entrusting airhostesses // ... the British Medical Association (BMA) has been urged to ... to conduct operations on patients. More than 130 doctors ...
    ... China have identified the deadly H5N1 virus in geese, ducks ... sparking fears of bird flu pandemic//. ,It has ... flu virus. This however is the first time that large-scale ... chickens. Infected chickens usually die within 24 hours of the ...
    ... West Bengal Chief Minister Buddhadeb Bhattacharya has pledged to ... ,The general secretary of Ganadarpan, Brojo Roy said ... in this cause." Ganadarpan is an NGO with which ... ,Bhattacharya joins other communist leaders like Jyoti Basu, Somnath ...
    Cached Medicine News:Health News:Doctors Protest Against Allowing Nurses To Perform Minor Surgeries 2Health News:Healthy, Bird Flu Infected Chickens In Chinese Markets 2
    ... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
    Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
    Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists....
    ... The SphygmoCor Mx Central Blood ... of the SphygmoCor Px system by ... aortic pressure waveform., ,Key cardiovascular parameters ... trended. These parameters include:, Central ...
    Medicine Products: